{"schema_version":"secwatch.filing_event.v1","accession":"0001636651-25-000011","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.005388+00:00","generated_at":"2026-05-16T21:15:02.344678+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ovid Therapeutics announces CEO succession, Q3 2025 loss, and pipeline progress","bullets":["Meg Alexander appointed CEO effective Jan 1, 2026; Jeremy Levin to become Executive Chairman.","Q3 2025 net loss $12.2M ($0.17/sh) vs $14.0M ($0.20) YoY; cash $25.6M at Sep 30.","Completed $81M private placement (up to $175M); cash runway extended into 2H 2028.","OV329 Phase 1 positive; Phase 2a in drug-resistant epilepsies planned Q2 2026.","OV350 IV data expected Q4 2025; OV4071 oral KCC2 activator to enter clinic Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001636651-25-000011","json":"https://secwatch.observer/filing/0001636651-25-000011.json","markdown":"https://secwatch.observer/filing/0001636651-25-000011.md","text":"https://secwatch.observer/filing/0001636651-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/0001636651-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/ovid-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:15:02.344678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}